Pfizer gets EU nod for ulcerative colitis drug Velsipity
The approval, applicable in all 27 countries of the European Union, is based on studies from two late-stage trials that showed the drug was effective and safe in eligible patients.
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-02-20 06:00 GMT | Update On 2024-03-22 09:42 GMT
Advertisement
Pfizer's drug to treat patients with an inflammatory bowel disease called ulcerative colitis has been approved by the European Commission, the company said on Monday.
The approval for Velsipity follows backing from the European Medicines Agency's panel of experts in December.
The drug was approved for use in patients aged 16 or older and who did not show adequate response or were intolerant to previous treatment, Pfizer said.
The approval, applicable in all 27 countries of the European Union, is based on studies from two late-stage trials that showed the drug was effective and safe in eligible patients.
Pfizer said Velsipity will be available in each of the member countries after the national processes are complete, including applications for reimbursement for the drug.
About 2.6 million people in Europe are living with ulcerative colitis, Pfizer says.
Velsipity, which was approved in the United States in October, belongs to a class of drugs used to regulate the body's immune response and is expected to compete with Bristol Myers Squibb's Zeposia.
Pfizer has also sought regulatory approvals for the drug in Australia, India and the UK, among others.
Leerink Partners in October estimated the drug's 2030 sales at $2.2 billion.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.